New frontiers-accelerator mass spectrometry (AMS): Recommendation for best practices and harmonization from Global Bioanalysis Consortium Harmonization Team.
The technique of accelerator mass spectrometry (AMS) is applicable to the analysis of a wide range of trace elemental isotopes. However, in the context of the pharmaceutical industry, it is invariably used to measure radiocarbon ((14)C). There are two broad modes of application: analysis of total (14)C sometimes termed "direct AMS" and analysis of specific (14)C-labelled analytes in a variety of matrices following some method of isolation. It is the latter application which is within the remit of the GBC team, and the team has made efforts to propose harmonized recommendations for the validation of AMS when used in a regulatory bioanalytical mode, i.e. the quantification of specific analyte(s) using liquid chromatography with off-line detection by AMS now known as "LC + AMS". The GBC team has reached a position where they have agreed to many aspects, but also differ on some aspects of what constitutes a bioanalytical assay validation in support of clinical studies using this technology. The detail of most of this will be covered under separate publication(s), but for the purposes of this paper, we have outlined the points of consensus. The purpose of this article is not to provide a roadmap for validation of LC + AMS assays, but to highlight agreements amongst the industry representative experts and the practitioners, as well as identifying specific areas essential for establishing assay quality but where additional discussion is required to reach agreement.
David Jack Centre, GlaxoSmithKline Research and Development Ltd., Park Road, Ware, Herts, SG12 0DP, UK, graeme.c.young@gsk.com.
Graeme C
GC
Young
Mark
M
Seymour
Stephen R
SR
Dueker
Philip
P
Timmerman
Ali
A
Arjomand
Kohei
K
Nozawa
D001681:Biological Assay / Q000379:methods*; D002853:Chromatography, Liquid / Q000379:methods*; D007391:International Cooperation; D013058:Mass Spectrometry / Q000379:methods*